HIT TO LEAD CHEMISTRY UNDER PERFORMANCE AREA 2 OF ID/IQ CONTRACT NO. HHSN271201800001I

NIH RePORTER · NIH · N01 · $456,391 · view on reporter.nih.gov ↗

Abstract

This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management. Hit to Lead Chemistry (Task Order)) is hereby awarded to Curia Global, Inc. (Contractor) under ID/IQ Contract HHSN271201800001I (Parent Contract). to develop structure activity relationship (SAR) analysis and design, synthesis, in vitro absorption, distribution, metabolism, excretion and toxicology (ADMET), computational chemistry/Computer Aided Drug Discovery (CADD), and compound logistics of storage and shipping to support the Contributor in developing a novel therapeutic effective in treating pain. This will be achieved by advancing the SAR/SPR of their small molecule prodrugs of starting small molecules utilizing their assays and in vitro ADMET to identify novel, prodrugs.

Key facts

NIH application ID
11041795
Project number
271201800001I-P00002-759502200007-1
Recipient
ALBANY MOLECULAR RESEARCH, INC.
Principal Investigator
MATT SURMAN
Activity code
N01
Funding institute
NIH
Fiscal year
2024
Award amount
$456,391
Award type
Project period
2022-09-28 → 2024-12-31